Esperite N.V.: announces termination of audit engagement in relation to 2018 annual report
04 Juillet 2019 - 08:58AM
Esperite N.V.: announces termination of audit engagement in
relation to 2018 annual report
ESPERITE (ESP) announces termination of
audit engagement in relation to 2018 annual report
Amsterdam, The
Netherlands – 3 July 2019Esperite N.V.
(Euronext: ESP, “Esperite”) announces that its
statutory auditor, accon avm controlepraktijk B.V.
(“Accon”) has terminated the audit engagement in
relation to the 2018 annual report due to the non-observance by
Esperite of a deadline imposed by Accon. The Board of Esperite
considers the termination ineffective due to the lack of a
reasonable notice period, and is currently assessing whether to
initiate legal proceedings against Accon.
On 21 March 2019, Accon informed Esperite that
from the financial year 2019 onwards it plans to shift its focus to
providing accounting and advisory services to organisations in the
public domain and SMEs only. For strategic reasons, Accon has
decided to convert its license to audit public interest entities
(PIE) into a regular license under the Dutch Accounting Firms
(Supervision) Act as of 30 June 2019.
Accon successfully agreed an extension of its
PIE licence with the Netherlands Authority for the Financial
Markets (AFM) in order to complete the audit of Esperite’s 2018
annual report. However, today Accon informed Esperite that it has
agreed with the AFM to hand in its PIE licence as of today, which
means that Accon is no longer in the position to continue and
finalize the audit of Esperite’s 2018 annual report.
Esperite will continue to strive to publish its
2018 annual report as promptly as practicable, but such publication
is likely to be considerably delayed if Esperite is forced to
engage a new statutory auditor. Esperite will update its
shareholders and other stakeholders on any significant developments
if and when appropriate.
About ESPERITE N.V.ESPERITE Group (Euronext:
ESP), listed at Euronext Amsterdam and Paris, is a leading
international company in regenerative and predictive medicine
established in 2000.
To learn more about ESPERITE Group, or to book
an interview with CEO Frederic Amar: +31 575 548 998 –
ir@esperite.com or visit the website at www.esperite.com.
***This press release contains inside information
as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014
(Market Abuse Regulation).
- Esperite N.V.: announces termination of audit engagement in
relation to 2018 annual report